John L. Hays

2.2k total citations
98 papers, 1.6k citations indexed

About

John L. Hays is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, John L. Hays has authored 98 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 32 papers in Reproductive Medicine and 26 papers in Molecular Biology. Recurrent topics in John L. Hays's work include Ovarian cancer diagnosis and treatment (31 papers), PARP inhibition in cancer therapy (16 papers) and Intraperitoneal and Appendiceal Malignancies (11 papers). John L. Hays is often cited by papers focused on Ovarian cancer diagnosis and treatment (31 papers), PARP inhibition in cancer therapy (16 papers) and Intraperitoneal and Appendiceal Malignancies (11 papers). John L. Hays collaborates with scholars based in United States, Canada and Germany. John L. Hays's co-authors include Kristin Bixel, James L. Chen, Elise C. Kohn, Raquel E. Reinbolt, Christina M. Annunziata, Lori M. Minasian, Monica Hagan Vetter, Anne M. Noonan, David E. Cohn and Sherif Abdel‐Misih and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

John L. Hays

91 papers receiving 1.5k citations

Peers

John L. Hays
Sabrina Chiara Cecere Italy
Irina Linkov United States
Carmela Pisano Italy
Jérôme Alexandre France
Yasuyuki Hirashima Japan
Vanda Salutari Italy
Véronique D’Hondt France
Frauke Bentzien United States
Marilena Di Napoli Italy
Scott McMeekin United States
Sabrina Chiara Cecere Italy
John L. Hays
Citations per year, relative to John L. Hays John L. Hays (= 1×) peers Sabrina Chiara Cecere

Countries citing papers authored by John L. Hays

Since Specialization
Citations

This map shows the geographic impact of John L. Hays's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John L. Hays with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John L. Hays more than expected).

Fields of papers citing papers by John L. Hays

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John L. Hays. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John L. Hays. The network helps show where John L. Hays may publish in the future.

Co-authorship network of co-authors of John L. Hays

This figure shows the co-authorship network connecting the top 25 collaborators of John L. Hays. A scholar is included among the top collaborators of John L. Hays based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John L. Hays. John L. Hays is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brown, Leanne, David Su, Kiran K. Turaga, et al.. (2025). Consensus guideline for the management of peritoneal mesothelioma. Cancer. 131(13). e35868–e35868.
2.
3.
Brasky, Theodore M., Leah R. Jager, Holli A. Loomans‐Kropp, et al.. (2024). Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative. Cancer Epidemiology Biomarkers & Prevention. 33(9). 1203–1210. 1 indexed citations
4.
Brasky, Theodore M., Sara Conroy, Scott A. Strassels, et al.. (2023). Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer. Cancer Research Communications. 3(9). 1917–1926. 8 indexed citations
5.
Brasky, Theodore M., Roberta M. Ray, Sandi L. Navarro, et al.. (2023). Supplemental B-Vitamins and Risk of Upper Gastrointestinal Cancers in the Women’s Health Initiative. Nutrition and Cancer. 75(4). 1103–1108. 1 indexed citations
6.
Werner, Theresa L., Nehal J. Lakhani, William J. Edenfield, et al.. (2022). 32 UPGRADE: phase 1 combination trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer. Gynecologic Oncology Reports. 44. S16–S16. 1 indexed citations
7.
Richardson, Debra J., Jill Tseng, Theresa L. Werner, et al.. (2022). 33 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer. Gynecologic Oncology Reports. 44. S16–S17. 2 indexed citations
8.
Ramsey, Mitchell L., Rachel Pearlman, Laith Abushahin, et al.. (2022). Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake. Familial Cancer. 22(1). 91–97. 23 indexed citations
9.
10.
Backes, Floor, Lai Wei, Min Chen, et al.. (2021). Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. Gynecologic Oncology. 162(3). 619–625. 13 indexed citations
11.
Krook, Melanie A., Max Wilberding, Kelly M. Bailey, et al.. (2020). Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. Molecular Cancer Therapeutics. 19(3). 847–857. 106 indexed citations
12.
Hamilton, E.P., Rebecca C. Arend, Christina Chu, et al.. (2020). 839P A phase Ib/II study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer. Annals of Oncology. 31. S629–S630. 1 indexed citations
13.
Dorayappan, Kalpana Deepa Priya, Miranda L. Gardner, Colin L. Hisey, et al.. (2019). A Microfluidic Chip Enables Isolation of Exosomes and Establishment of Their Protein Profiles and Associated Signaling Pathways in Ovarian Cancer. Cancer Research. 79(13). 3503–3513. 88 indexed citations
14.
Datta, Jharna, Senthilkumar Damodaran, Jharna Miya, et al.. (2017). Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398. Molecular Cancer Therapeutics. 16(4). 614–624. 72 indexed citations
15.
Chen, James L., et al.. (2016). Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease. Molecular Cancer Research. 15(1). 26–34. 34 indexed citations
16.
ElNaggar, Adam C., John L. Hays, & James L. Chen. (2016). Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series. PLoS ONE. 11(6). e0156985–e0156985. 4 indexed citations
17.
ElNaggar, Adam C., John Wallbillich, Kristin Bixel, et al.. (2016). Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene. 36(2). 168–181. 96 indexed citations
18.
Bixel, Kristin & John L. Hays. (2015). Olaparib in the management of ovarian cancer. Pharmacogenomics and Personalized Medicine. 8. 127–127. 43 indexed citations
19.
Lee, Jung Min, John L. Hays, Anne M. Noonan, et al.. (2012). Feasibility and safety of sequential research‐related tumor core biopsies in clinical trials. Cancer. 119(7). 1357–1364. 23 indexed citations
20.
Hays, John L. & Stanley J. Watowich. (2003). Oligomerization-induced Modulation of TPR-MET Tyrosine Kinase Activity. Journal of Biological Chemistry. 278(30). 27456–27463. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sabrina Chiara Cecere Breakdown of academic impact, for papers by Irina Linkov Breakdown of academic impact, for papers by Carmela Pisano Breakdown of academic impact, for papers by Jérôme Alexandre Breakdown of academic impact, for papers by Yasuyuki Hirashima Breakdown of academic impact, for papers by Vanda Salutari Breakdown of academic impact, for papers by Véronique D’Hondt Breakdown of academic impact, for papers by Frauke Bentzien Breakdown of academic impact, for papers by Marilena Di Napoli Breakdown of academic impact, for papers by Scott McMeekin
Rankless by CCL
2026